Novavax Announces COVID-19 Vaccine Clinical Development Progress
The Pharma Data
NOVEMBER 30, 2020
Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today provided an update on its COVID-19 vaccine program. availability of efficacy data depends on the illness rate in South Africa and may be available as soon as the first quarter 2021. GAITHERSBURG, Md.,
Let's personalize your content